Ovarian Cancer Clinical Trial

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Summary

This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion criteria:

Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Has received one prior platinum-based chemotherapy regimen(cisplatin,carboplatin, or oxaliplatin).
Has psychological, familial, sociological or geographical condition that does not permit compliance with the protocol.
Is on a specifically prohibited medication or requires these medications during treatment with GW786034.

Exclusion criteria:

Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy with in the last 28 days and has not recovered from such prior therapy.
Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or higher).
Currently taking warfarin.
Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

35

Study ID:

NCT00281632

Recruitment Status:

Completed

Sponsor:

GlaxoSmithKline

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

GSK Investigational Site
Atlanta Georgia, 30342, United States
GSK Investigational Site
Austin Texas, 78731, United States
GSK Investigational Site
Bedford Texas, 76022, United States
GSK Investigational Site
Dallas Texas, 75246, United States
GSK Investigational Site
Fort Worth Texas, 76104, United States
GSK Investigational Site
Randwick New South Wales, 2031, Australia
GSK Investigational Site
Herston Queensland, 4029, Australia
GSK Investigational Site
Melbourne , 3084, Australia
GSK Investigational Site
Singapore , 11907, Singapore
GSK Investigational Site
Singapore , 22989, Singapore

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

35

Study ID:

NCT00281632

Recruitment Status:

Completed

Sponsor:


GlaxoSmithKline

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider